- UroToday Home
- Urologic Oncology
The Latest Bladder Cancer Research
Recent Abstracts
-
Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer.Bladder CancerAugust 9, 2022
-
Diagnostic Value of the Vesical Imaging-Reporting and Data System in Bladder Urothelial Carcinoma with Variant Histology.Bladder CancerAugust 9, 2022
-
Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer.Bladder CancerAugust 9, 2022
-
First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin.Bladder CancerAugust 8, 2022
-
Lymphocyte-to-Monocyte Ratio (LMR) During Induction Is a Better Predictor Than Preoperative LMR in Patients Receiving Intravesical Bacillus Calmette -Guerin for Non-Muscle-Invasive Bladder Cancer.Bladder CancerAugust 8, 2022
-
Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma.Bladder CancerAugust 5, 2022
-
RNA-based urinary assays for non-muscle invasive bladder cancer.Bladder CancerAugust 5, 2022
-
MTAP Status and Antifolate Therapy in Cancers with 9p21 Loss - Expert CommentaryBladder CancerAugust 4, 2022
-
Radical cystectomy and women's sexual health - can we do better?Bladder CancerAugust 4, 2022
-
Immunogenomic Characteristics of Cell-Death-Associated Genes with Prognostic Implications in Bladder Cancer.Bladder CancerAugust 4, 2022
Beyond the Abstracts
-
En Bloc Versus Conventional Transurethral Resection of Bladder Tumors: A Single-center Prospective Randomized Non inferiority Trial - Beyond the AbstractBladder CancerAugust 3, 2022
-
C-Reactive Protein Flare Predicts Response to Anti-PD-(L)1 Immune Checkpoint Blockade in Metastatic Urothelial Carcinoma - Beyond the AbstractBladder CancerJuly 27, 2022
-
Treatment Trends for Muscle-Invasive Bladder Cancer in Germany from 2006 to 2019 - Beyond the AbstractBladder CancerJuly 26, 2022
-
The Learning Curve in Bladder MRI Using VI-RADS Assessment Score During an Interactive Dedicated Training Program - Beyond the AbstractBladder CancerJuly 20, 2022
-
Systemic Therapy Issues: Immunotherapy in Nonmetastatic Urothelial Cancer - Beyond the AbstractBladder CancerJuly 19, 2022
-
What Did We Learn from ESMO 2021, and What’s Next? A Peer-Reviewed Podcast with a Patient Advocate and Physician - Beyond the AbstractBladder CancerJuly 12, 2022
-
Adjuvant Chemotherapy Versus Observation Following Radical Cystectomy for Locally Advanced Urothelial Carcinoma of the Bladder - Beyond the AbstractBladder CancerJune 30, 2022
-
Combined miRNA and SERS Urine Liquid Biopsy for the Point-of-Care Diagnosis and Molecular Stratification of Bladder Cancer - Beyond the AbstractBladder CancerJune 23, 2022
-
Contemporary Staging for Muscle-Invasive Bladder Cancer: Accuracy and Limitations - Beyond the AbstractBladder CancerJune 22, 2022
-
Characterizing Molecular Subtypes of High-Risk Non-Muscle-Invasive Bladder Cancer in African American Patients - Beyond the AbstractBladder CancerJune 21, 2022
